(29 days)
Not Found
No
The device description and performance studies focus on the physical characteristics and mechanical performance of a peripherally inserted central catheter, with no mention of AI or ML capabilities.
No.
The device is a peripherally inserted central catheter used for administering therapy, not the therapy itself. Its function is to provide access for intravenous therapy, blood sampling, and power injection of contrast media, which are diagnostic or delivery functions, not therapeutic.
No
Explanation: The device is a peripherally inserted central catheter used for therapy, blood sampling, and contrast media injection. While blood sampling and contrast media injection are parts of diagnostic procedures, the device itself is a tool for delivery/access and not a standalone diagnostic device that interprets data or provides a diagnosis.
No
The device description clearly describes a physical catheter and associated accessories, not a software application.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information about a person's health. This testing is done outside the body (in vitro).
- Device Function: The Xcela Power Injectable PICC is a catheter inserted into the body to provide access to the central venous system. Its purpose is to deliver substances (medications, nutrients, contrast media) and to draw blood from the body.
- Intended Use: The intended use clearly describes its function as a means of accessing the central venous system for therapy and blood sampling. It does not describe any testing or analysis of specimens outside the body.
Therefore, based on the provided information, the Xcela Power Injectable PICC is a medical device used in vivo (within the body) and does not fit the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Xcela Power Injectable PICC is indicated for short- or long-term peripheral access to the central venous system for intravenous therapy, including but not limited to, the administrations and nutrients, the sampling of blood, and for power injection of contrast media. Maximum power injection flow rate:
4F Single Lumen, 45 cm - 4 mL/sec
4F Single Lumen, 55 cm - 3.5 mL/sec
5F Single Lumen, 55 cm - 5 mL/sec
5F Dual Lumen, 45 cm - 5 mL/sec
5F Dual Lumen, 55 cm - 4 mL/sec
6F Dual Lumen, 55 cm - 5 mL/sec
Product codes (comma separated list FDA assigned to the subject device)
LJS
Device Description
The Xcela Power Injectable PICC is indicated for short- or long-term peripheral access to the central yenous system for intravenous therapy, including but not limited to, the administration of fluids, medications and nutrients, the sampling of blood, and for power injection of contrast media. Maximum power injection flow rate:
- 4 Fr SL, 45 cm-4 mL/sec
- . 4 Fr SL, 55 cm=3.5 mL/sec
- . 5 Fr SL, 55 cm=5 mL/sec
- 5 Fr DL, 45 cm-5 mL/sec
- 5 Fr DL, 55 cm=4 mL/sec
- . 6 Fr DL, 55 cm=5 mL/sec.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
central venous system
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The XP is substantially equivalent to Navilyst predicate devices based on comparison of technological characteristics and the results of non-clinical tests which included the performance evaluation conducted in accordance with the following FDA guidance documents, international standards, and testing which included:
- . EN ISO 10555-1:2009, Sterile, Single use intravascular catheters - Part 1: General Requirements
- . EN ISO 10555-3:1997 Corrigendum 1:2002, Sterile, Single-Use Intravascular Catheters -Part 3: Central Venous Catheters
- . FDA's "Guidance on Premarket Notification [510(K)] Submissions for Short-Term and Long-Term Intravascular Catheters dated March 16, 1995"
The results of the non-clinical testing and a comparison of similarities and differences demonstrate that the proposed and predicate devices are substantially equivalent.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5970 Percutaneous, implanted, long-term intravascular catheter.
(a)
Identification. A percutaneous, implanted, long-term intravascular catheter is a device that consists of a slender tube and any necessary connecting fittings, such as luer hubs, and accessories that facilitate the placement of the device. The device allows for repeated access to the vascular system for long-term use of 30 days or more, and it is intended for administration of fluids, medications, and nutrients; the sampling of blood; and monitoring blood pressure and temperature. The device may be constructed of metal, rubber, plastic, composite materials, or any combination of these materials and may be of single or multiple lumen design.(b)
Classification. Class II (special controls) Guidance Document: “Guidance on Premarket Notification [510(k)] Submission for Short-Term and Long-Term Intravascular Catheters.”
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human faces in profile, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 31, 2015
Navilyst Medical, Inc. Ms. Wanda Carpinella Director, Regulatory Affairs 26 Forest Street Marlborough, MA 01752
Re: K150527
Trade/Device Name: Xcela Power Injectable PICC Regulation Number: 21 CFR 880.5970 Regulation Name: Percutaneous, implanted, long-term intravascular catheter Regulatory Class: II Product Code: LJS Dated: February 27, 2015 Received: March 02, 2015
Dear Ms. Carpinella:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Tina
Kiang -S
for Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K150527
Device Name Xcela Power Injectable PICC
Indications for Use (Describe)
The Xcela Power Injectable PICC is indicated for short- or long-term peripheral access to the central venous system for intravenous therapy, including but not limited to, the administrations and nutrients, the sampling of blood, and for power injection of contrast media. Maximum power injection flow rate:
4F Single Lumen, 45 cm - 4 mL/sec
4F Single Lumen, 55 cm - 3.5 mL/sec
5F Single Lumen, 55 cm - 5 mL/sec
5F Dual Lumen, 45 cm - 5 mL/sec
5F Dual Lumen, 55 cm - 4 mL/sec
6F Dual Lumen, 55 cm - 5 mL/sec
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY FOR THE XCELA POWER INJECTABLE PICC
510(K) #: K150527
Date prepared: March 30, 2015
A. Sponsor
Navilyst Medical, Inc 26 Forest Street Marlborough, MA 01752
B. Contact
Wanda Carpinella Director, Regulatory Affairs 508-658-7929_wanda.carpinella@angiodynamics.com
OR
Brandon Brackett Specialist II, Global Regulatory Affairs 508-658-7940_brandon.brackett@angiodynamcis.com
C. Device Name
| Trade Name | Xcela Power Injectable PICC |
|---|---|
| Common/Usual Name | Peripherally Inserted Central Catheter |
| (PICC) | |
| Classification Name: | Percutaneous, Implanted, Long-Term |
| Intravascular Catheter | |
| Classification Regulation | 21CFR§880.5970, Class II |
| ProCode | LIS |
| Classification Panel | General Hospital |
D. Predicate Device
| Common/Usual Name | Peripherally Inserted Central Catheter
(PICC) |
|---------------------------|---------------------------------------------------------------|
| Classification Name: | Percutaneous, Implanted, Long-Term
Intravascular Catheter |
| Classification Regulation | 21CFR§880.5970, Class II |
| ProCode | LJS |
| Classification Panel | General Hospital |
| PreMarket Notification | K070002, Xcela Power Injectable PICC
K133264, NMI PICC III |
4
E. Device Description Intended Use
The Xcela Power Injectable PICC is indicated for short- or long-term peripheral access to the central yenous system for intravenous therapy, including but not limited to, the administration of fluids, medications and nutrients, the sampling of blood, and for power injection of contrast media. Maximum power injection flow rate:
- 4 Fr SL, 45 cm-4 mL/sec ●
- . 4 Fr SL, 55 cm=3.5 mL/sec
- . 5 Fr SL, 55 cm=5 mL/sec
- 5 Fr DL, 45 cm-5 mL/sec
- 5 Fr DL, 55 cm=4 mL/sec
- . 6 Fr DL, 55 cm=5 mL/sec
F. Summary of Similarities and Differences in Technological Characteristics and Performance
When compared to the predicate Xcela Power Injectable PICC (K070002), the proposed Xcela Power Injectable PICC incorporates changes that include: addition of an oversleeve to the extension tube, a new non-valved luer design, and inclusion of maximum flow rates into the indication statement - the same changes that were made to the predicate NMI PICC III in K133264. With the addition of these changes, the only difference between the proposed Xcela Power Injectable PICC and the predicate NMI PICC III (K133264) is that the catheter shaft of the proposed device does not contain Endexo – a polymer blended into the catheter shaft that reduces the accumulation of thrombus - whereas the predicate NMI PICC III's catheter shaft does. Please note: the predicate Xcela Power Injectable PICC (K070002) also does not contain Endexo.
All other aspects of the proposed devices, including packaging and sterilization, are identical to those of the predicate; no other changes are being proposed herein. In brief, both the proposed and predicate devices are:
- . intended for short- or long-term peripheral access to the central venous system for intravenous therapy, blood sampling, and power injection of contrast media;
- . available in single and multi-lumen configurations in a wide range of sized from 4F to 6F outside catheter diameter;
- . rated for maximum power injector settings up to 325 psi;
- . rated for maximum power injection flow rate up to 5 ml/second based on model; and
- available kitted with a range of procedural accessories for user convenience. .
G. Performance Data
The XP is substantially equivalent to Navilyst predicate devices based on comparison of technological characteristics and the results of non-clinical tests which included the performance evaluation conducted in accordance with the following FDA guidance documents, international standards, and testing which included:
- . EN ISO 10555-1:2009, Sterile, Single use intravascular catheters - Part 1: General Requirements
- . EN ISO 10555-3:1997 Corrigendum 1:2002, Sterile, Single-Use Intravascular Catheters -Part 3: Central Venous Catheters
- . FDA's "Guidance on Premarket Notification [510(K)] Submissions for Short-Term and Long-Term Intravascular Catheters dated March 16, 1995"
H. Conclusion
The results of the non-clinical testing and a comparison of similarities and differences demonstrate that the proposed and predicate devices are substantially equivalent.